Cargando…

Using Split Luminescent Biosensors for SARS‐CoV‐2 Antibody Detection in Serum, Plasma, and Blood Samples

Antibody detection assays are essential for evaluating immunity of individuals against a given virus, and this has been particularly relevant during the COVID‐19 pandemic. Current serology assays either require a laboratory setting and take >1 hr (i.e., enzyme‐linked immunosorbent assay [ELISA])...

Descripción completa

Detalles Bibliográficos
Autores principales: Elledge, Susanna K., Eigl, Ian, Phelps, Maira, McClinton, Khayla, Zhou, Xin X., Leung, Kevin K., Tato, Cristina M., Wells, James A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793882/
https://www.ncbi.nlm.nih.gov/pubmed/36200787
http://dx.doi.org/10.1002/cpz1.521
_version_ 1784859923901841408
author Elledge, Susanna K.
Eigl, Ian
Phelps, Maira
McClinton, Khayla
Zhou, Xin X.
Leung, Kevin K.
Tato, Cristina M.
Wells, James A.
author_facet Elledge, Susanna K.
Eigl, Ian
Phelps, Maira
McClinton, Khayla
Zhou, Xin X.
Leung, Kevin K.
Tato, Cristina M.
Wells, James A.
author_sort Elledge, Susanna K.
collection PubMed
description Antibody detection assays are essential for evaluating immunity of individuals against a given virus, and this has been particularly relevant during the COVID‐19 pandemic. Current serology assays either require a laboratory setting and take >1 hr (i.e., enzyme‐linked immunosorbent assay [ELISA]) or are rapid but only qualitative in nature and cannot accurately track antibody levels over time (i.e., lateral flow assay [LFA]). Therefore, there is a need for development of a rapid and simple but also quantitative assay that can evaluate antibody levels in patients accurately over time. We have developed an assay that uses a split nanoluciferase fused to the spike or nucleocapsid proteins of the SARS‐CoV‐2 virus to enable luminescent‐based detection of spike‐ or nucleocapsid‐binding antibodies in serum, plasma, and whole blood samples. The resulting approach is simple, rapid, and quantitative and is highly amenable to low‐/medium‐throughput scale using plate‐based assays, high‐throughput scale using robotics, and point‐of‐care applications. In this article, we describe how to perform the assay in a laboratory setting using a plate reader or liquid‐handling robotics and in a point‐of‐care setting using a handheld, battery‐powered luminometer. Together, these assays allow antibody detection to be easily performed in multiple settings by simplifying and reducing assay time in a laboratory or clinical environment and by allowing for antibody detection in point‐of‐care, nonlaboratory settings. © 2022 Wiley Periodicals LLC. Basic Protocol: SARS‐CoV‐2 antibody detection using the split‐luciferase assay on a medium‐throughput scale with a laboratory luminometer Alternate Protocol 1: High‐throughput‐based protocol for SARS‐CoV‐2 antibody detection using a robotic platform Alternate Protocol 2: Point‐of‐care‐based protocol for SARS‐CoV‐2 antibody detection using a handheld luminometer Support Protocol: Determining positive/negative cutoffs for test samples and standardizing the assay between days
format Online
Article
Text
id pubmed-9793882
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97938822023-01-25 Using Split Luminescent Biosensors for SARS‐CoV‐2 Antibody Detection in Serum, Plasma, and Blood Samples Elledge, Susanna K. Eigl, Ian Phelps, Maira McClinton, Khayla Zhou, Xin X. Leung, Kevin K. Tato, Cristina M. Wells, James A. Curr Protoc Protocol Antibody detection assays are essential for evaluating immunity of individuals against a given virus, and this has been particularly relevant during the COVID‐19 pandemic. Current serology assays either require a laboratory setting and take >1 hr (i.e., enzyme‐linked immunosorbent assay [ELISA]) or are rapid but only qualitative in nature and cannot accurately track antibody levels over time (i.e., lateral flow assay [LFA]). Therefore, there is a need for development of a rapid and simple but also quantitative assay that can evaluate antibody levels in patients accurately over time. We have developed an assay that uses a split nanoluciferase fused to the spike or nucleocapsid proteins of the SARS‐CoV‐2 virus to enable luminescent‐based detection of spike‐ or nucleocapsid‐binding antibodies in serum, plasma, and whole blood samples. The resulting approach is simple, rapid, and quantitative and is highly amenable to low‐/medium‐throughput scale using plate‐based assays, high‐throughput scale using robotics, and point‐of‐care applications. In this article, we describe how to perform the assay in a laboratory setting using a plate reader or liquid‐handling robotics and in a point‐of‐care setting using a handheld, battery‐powered luminometer. Together, these assays allow antibody detection to be easily performed in multiple settings by simplifying and reducing assay time in a laboratory or clinical environment and by allowing for antibody detection in point‐of‐care, nonlaboratory settings. © 2022 Wiley Periodicals LLC. Basic Protocol: SARS‐CoV‐2 antibody detection using the split‐luciferase assay on a medium‐throughput scale with a laboratory luminometer Alternate Protocol 1: High‐throughput‐based protocol for SARS‐CoV‐2 antibody detection using a robotic platform Alternate Protocol 2: Point‐of‐care‐based protocol for SARS‐CoV‐2 antibody detection using a handheld luminometer Support Protocol: Determining positive/negative cutoffs for test samples and standardizing the assay between days John Wiley and Sons Inc. 2022-10-06 2022-10 /pmc/articles/PMC9793882/ /pubmed/36200787 http://dx.doi.org/10.1002/cpz1.521 Text en © 2022 Wiley Periodicals LLC. This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.
spellingShingle Protocol
Elledge, Susanna K.
Eigl, Ian
Phelps, Maira
McClinton, Khayla
Zhou, Xin X.
Leung, Kevin K.
Tato, Cristina M.
Wells, James A.
Using Split Luminescent Biosensors for SARS‐CoV‐2 Antibody Detection in Serum, Plasma, and Blood Samples
title Using Split Luminescent Biosensors for SARS‐CoV‐2 Antibody Detection in Serum, Plasma, and Blood Samples
title_full Using Split Luminescent Biosensors for SARS‐CoV‐2 Antibody Detection in Serum, Plasma, and Blood Samples
title_fullStr Using Split Luminescent Biosensors for SARS‐CoV‐2 Antibody Detection in Serum, Plasma, and Blood Samples
title_full_unstemmed Using Split Luminescent Biosensors for SARS‐CoV‐2 Antibody Detection in Serum, Plasma, and Blood Samples
title_short Using Split Luminescent Biosensors for SARS‐CoV‐2 Antibody Detection in Serum, Plasma, and Blood Samples
title_sort using split luminescent biosensors for sars‐cov‐2 antibody detection in serum, plasma, and blood samples
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793882/
https://www.ncbi.nlm.nih.gov/pubmed/36200787
http://dx.doi.org/10.1002/cpz1.521
work_keys_str_mv AT elledgesusannak usingsplitluminescentbiosensorsforsarscov2antibodydetectioninserumplasmaandbloodsamples
AT eiglian usingsplitluminescentbiosensorsforsarscov2antibodydetectioninserumplasmaandbloodsamples
AT phelpsmaira usingsplitluminescentbiosensorsforsarscov2antibodydetectioninserumplasmaandbloodsamples
AT mcclintonkhayla usingsplitluminescentbiosensorsforsarscov2antibodydetectioninserumplasmaandbloodsamples
AT zhouxinx usingsplitluminescentbiosensorsforsarscov2antibodydetectioninserumplasmaandbloodsamples
AT leungkevink usingsplitluminescentbiosensorsforsarscov2antibodydetectioninserumplasmaandbloodsamples
AT tatocristinam usingsplitluminescentbiosensorsforsarscov2antibodydetectioninserumplasmaandbloodsamples
AT wellsjamesa usingsplitluminescentbiosensorsforsarscov2antibodydetectioninserumplasmaandbloodsamples